Bronstein, Gewirtz & Grossman, LLC Announces Class Action Lawsuit Against GSK plc for Alleged Securities Law Violations
New York, NY – March 25, 2025
Bronstein, Gewirtz & Grossman, LLC, a leading national securities fraud law firm, reminds investors that a class action lawsuit has been filed against GSK plc (“GSK” or “the Company”) (NYSE:GSK) and certain of its officers. The lawsuit, filed in the United States District Court for the Eastern District of Pennsylvania, alleges that the defendants violated the federal securities laws by making false and misleading statements and/or failing to disclose material information during the Class Period, which is defined as the period from February 5, 2020, to August 14, 2022.
Class Definition
This lawsuit seeks to recover damages on behalf of all persons and entities that purchased or otherwise acquired GSK American Depositary Receipts (“ADRs”) during the Class Period. If you purchased GSK ADRs during the Class Period, you may be eligible to participate in this class action. ADRs are negotiable certificates that represent ownership in a foreign company’s securities, and they trade on U.S. stock exchanges as if they were ordinary shares.
Alleged Misconduct
The complaint alleges that during the Class Period, GSK and its officers made false and misleading statements and/or failed to disclose material information regarding the Company’s business, operations, and financial condition. Specifically, the complaint alleges that the defendants failed to disclose that GSK was experiencing significant issues with its vaccine business, particularly with respect to its COVID-19 vaccine, which was expected to be a major contributor to the Company’s revenue growth. The complaint also alleges that the defendants failed to disclose that GSK was experiencing manufacturing issues with its respiratory syncytial virus (“RSV”) vaccine, which was also expected to be a significant contributor to the Company’s revenue growth.
Impact on Individual Investors
If you purchased GSK ADRs during the Class Period and suffered losses as a result of the alleged securities law violations, you may be eligible to participate in this class action. The damages you may be entitled to recover include any losses you incurred as a result of purchasing GSK ADRs during the Class Period, as well as any losses you may have incurred as a result of selling your GSK ADRs at a price lower than what you paid during the Class Period. You may also be entitled to recover any costs and fees incurred in connection with the purchase and sale of your GSK ADRs.
Impact on the World
The impact of this lawsuit on the world may depend on the outcome of the case. If the plaintiffs are successful, it could lead to increased scrutiny of pharmaceutical companies’ reporting practices, particularly with respect to their vaccine businesses. It could also lead to increased investor awareness of the risks associated with investing in companies that rely heavily on vaccine sales for revenue growth. Additionally, if the defendants are found liable, it could result in significant damages being paid to the class of plaintiffs, which could have ripple effects on the Company’s financial condition and its ability to invest in research and development.
Conclusion
Bronstein, Gewirtz & Grossman, LLC continues to investigate potential securities fraud claims against GSK and its officers. If you purchased GSK ADRs during the Class Period and suffered losses as a result of the alleged securities law violations, you are encouraged to contact the firm as soon as possible. You may be able to recover your losses through this class action.
- Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against GSK plc and certain of its officers for alleged securities law violations.
- The lawsuit seeks to recover damages on behalf of all persons and entities that purchased or otherwise acquired GSK American Depositary Receipts (“ADRs”) during the Class Period, which is defined as February 5, 2020, to August 14, 2022.
- The complaint alleges that the defendants made false and misleading statements and/or failed to disclose material information regarding the Company’s vaccine business, particularly with respect to its COVID-19 and RSV vaccines.
- Individual investors who purchased GSK ADRs during the Class Period and suffered losses may be eligible to participate in this class action.
- The impact of this lawsuit on the world may depend on the outcome of the case, and could result in increased scrutiny of pharmaceutical companies’ reporting practices and increased investor awareness of the risks associated with investing in vaccine-reliant companies.
